文献速递血栓与止血

暴露于抗抑制物凝血复合物的患者血栓栓塞事件发生率:40年已发表数据的荟萃分析

Thromboembolic event rate in patients exposed to anti-inhibitor coagulant complex: a meta-analysis of 40-year published data.
PubMed 文献 · Blood Adv · 2017-12-12

该研究按PRISMA指南系统检索Medline至2017年3月的文献,纳入39项研究(1980-2016),采用基于泊松分布的广义线性混合模型荟萃分析抗抑制物凝血复合物(AICC)暴露后血栓栓塞事件(TEE)发生率。汇总TEE发生率为每10万次AICC输注2.87次(95%CI 0.32-25.40),作者认为这些发现为AICC近40年的安全性提供了有力证据。

要点

  • 汇总TEE发生率为每10万次AICC输注2.87次(95%CI 0.32-25.40)。
  • 回顾性研究中TEE发生率为每10万次输注5.42次(95%CI 0.92-31.82)。
  • 预防性用药未见TEE报告,按需用药发生率为每10万次输注5.09次(95%CI 0.01-1795.60)。

核心结论

  • 这些发现为AICC近40年已发表研究中的安全性提供了有力证据。

研究设计与样本

  • 按PRISMA指南系统检索Medline自建库至2017年3月的文献,纳入39项研究(1980-2016)。
  • 采用基于泊松分布的广义线性混合模型荟萃分析估计TEE发生率。

主要发现

  • 共报告46例TEE,其中13例为弥散性血管内凝血,11例为心肌梗死,3例为血栓性脑血管意外。
  • 汇总TEE发生率为每10万次AICC输注2.87次(95%CI 0.32-25.40)。
  • 回顾性研究中TEE发生率为每10万次AICC输注5.42次(95%CI 0.92-31.82),前瞻性研究中为每10万次输注1.09次(95%CI 0.01-238.77)。
  • 按需给药时TEE发生率为每10万次AICC输注5.09次(95%CI 0.01-1795.60),预防性给药未见TEE报告。
  • 先天性血友病患者的估计发生率为每10万次输注<0.01次。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Anti-inhibitor coagulant complex (AICC), an activated prothrombin complex concentrate, has been available for the treatment of patients with inhibitors since 1977, and thromboembolic events (TEEs) have been reported after infusion of AICC in patients with congenital or acquired hemophilia. With the aim of estimating the TEE incidence rate (IR) related to AICC exposure in these patients, a systematic review of the literature was carried out in Medline, according to PRISMA guidelines, from inception date to March 2017. The IR of TEEs was estimated through a meta-analytic approach by using a generalized linear mixed model based on a Poisson distribution. Thirty-nine studies were included (1980-2016). Overall, 46 TEEs were reported; of these, 13 were reported as disseminated intravascular coagulations, 11 as myocardial infarctions, and 3 as thrombotic cerebrovascular accidents. The pooled TEE IR was 2.87 (95% confidence interval [CI], 0.32-25.40) per 100 000 AICC infusions (5.42 in retrospective studies [95% CI, 0.92-31.82]; 1.09 in prospective studies [95% CI, 0.01-238.77]). The TEE rate was 5.09 (95% CI, 0.01-1795.60) per 100 000 AICC infusions administered on demand, whereas no TEEs were reported with prophylaxis. Interestingly, the estimated IR in patients with congenital hemophilia was <0.01 per 100 000 infusions. These findings provide robust evidence of safety of AICC over almost 40 years of published studies.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Rota M, Cortesi PA, Crea R, et al. Thromboembolic event rate in patients exposed to anti-inhibitor coagulant complex: a meta-analysis of 40-year published data. Blood Adv. 2017. PMID: 29296916. doi:10.1182/bloodadvances.2017011536

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。